Document is current
Any future updates will be listed below
-
Authors
Hao, Shumeng https://orcid.org/0000-0002-9114-0759
Zhang, Sulin
Ye, Jialin https://orcid.org/0000-0002-6520-8844
Chen, Lifan
Wang, Yan
Pei, Siyu
Zhu, Qingchen
Xu, Jing
Tao, Yongzhen
Zhou, Neng
Yin, Huiyong https://orcid.org/0000-0001-7049-1560
Duan, Cai‐Wen
Mao, Chaoming https://orcid.org/0000-0002-2915-0921
Zheng, Mingyue
Xiao, Yichuan https://orcid.org/0000-0001-7804-6971
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82030041)
Strategic Priority Research Program of the Chinese Academy of Sciences (XDB39030300)
National Key R&D Program of China (2018YFA0902703)
National Key R&D Program of China (2018YFA0107201)
Science and Technology Commission of Shanghai Municipality (21140905000)
Science and Technology Commission of Shanghai Municipality (20XD1424600)
China Postdoctoral Science Foundation (2021M693272)
China Postdoctoral Science Foundation (2021M700160)
China Postdoctoral Science Foundation (2021M702163)
CAS Key Laboratory of Tissue Microenvironment and Tumor
CAS Project for Young Scientist in Basic Research (YSBR‐076)
Youth Innovation Promotion Association CAS (2023296)
- License Information
-
More Information
Article History
Received: 2 February 2023
Accepted: 8 February 2023
First Online: 2 March 2023
Disclosure and competing interests statement
: YX, MZ, SH, SZ, LC, and JY have filed a patent application regarding the generation and application in inflammatory diseases of DC‐Gonib32 and its derivatives. The authors declare that they have no conflict of interest.
Free to read: This content has been made available to all.
